

Checkpoint inhibitor-associated immune arthritis

et al

	Detailed characteristics of the 86 cases
Caaçe, c	·

Las ${\bf \hat{e}}_{\perp}$, $A{\bf \hat{k}}_{\perp}$ as $d,^1$ $B{\bf \hat{k}}_{\perp}$, d ς e Leb ${\bf \hat{k}}_{\perp}$ -V ${\bf \hat{k}}_{\perp}$ e $_{\star},^2$ J e-ETe SaTe $^{-2}$

¹Department of Rheumatology, Hôpitaux Universitaires de Strasbourg & INSERM UMRS-1109, Strasbourg, France

²AP-HP, Pitié-Salpêtrière Hospital, Department ofPharmacology, CIC-1421, Pharmacovigilance Unit; INSERM, UMR ICAN 1166;Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine; Institute ofCardiometabolism and Nutrition (ICAN), F-75013, Paris, France

C e A dè ce, Professor Laurent Arnaud, Department of Rheumatology Hôpitaux Universitaires de Strasbourg & INSERM UMRS-1109 Strasbourg France; laurent.arnaud@chru-strasbourg.fr



C e 🐴 dè ce

Cì, b, _ All authors analysed the data and wrote the manuscript.

FX d The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

C Aet i e e . None declared.

Pa, 崔 , cì, 🌲 , Not required.

P & a ce a d kee e e Not commissioned; internally peer reviewed.

 $\hfill {\ensuremath{\mathbb C}}$ Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.



T c, e Arnaud L, Lebrun-Vignes B, Salem J-E. Ann Rheum Dis 2019;78:e68.

Received 26 March 2018 Revised 18 April 2018 Accepted 19 April 2018 Published Online First 3 May 2018



- ▶ http://dx.doi.org/10.1136/annrheumdis-2018-213691
- Ann Rheum Dis 2019;78:e68. doi:10.1136/annrheumdis-2018-213470

REFERENCES

- 1 Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393–8.
- 2 Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377:1824–35.
- 3 Kong YC, Flynn JC. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol 2014;5:206.
- 4 Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933.
- 5 Lindquist M. VigiBase, the WHO Global ICSR Database system: basic facts. Drug Inf J 2008;42:409–19.
- 6 Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;JCO.2017.77.638.